BridgeMD
HiPRESS study
EU CTIS ID: 2024-513598-33-00
What this study is testing
To determine if low-dose argipressin decreases cumulative intraoperative fluid administration during CRS-HIPEC surgery compared to standard noradrenaline when using a standard GDT protocol
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- patients scheduled to undergo CRS-HIPEC
You likely can't join if
- Known underlying heart disease [New York Heart Association (NYHA) class III or IV and/or known left ventricular ejection fraction (LVEF) < 40%];
- Known unstable coronary artery disease;
- Stroke, head injury or carotid stenosis;
- Terminal kidney failure (preoperative estimated glomerular filtration rate <15 mL/min);
- Patients in whom POCUS is not possible or assessment of fluid status is unreliable e.g. BMI> 40, pulmonary fibrosis
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.